China Deal Monitor: Clover Biopharma raises $43m Series B and more updates

Clover Biopharmaceuticals, a clinical-stage biotechnology firm, has gathered 304 million yuan ($43 million) in its Series B round of financing led by Delos Capital and Lapam Capital, per a company statement.